Surgeons in theatre using
Protect. Beyond with PREVENA™ Therapy
  • The impact of SARS-CoV2 has everyone trying to manage patient care with a sharp eye on resources. With a focus on OR efficiency, minimizing prolonged stays and reducing readmissions and preventable complications is vital to patient flow and facility economics. As you look for solutions that provide extended value, it may be time to consider how PREVENA™ Therapy protects you, your patients, and your practice well beyond the incision site.


The Power of PREVENA™ Therapy

  • All fields are required unless indicated optional

  •  
  • 3M takes your privacy seriously. 3M and its authorized third parties will use the information you provided in accordance with our Privacy Policy to send you communications which may include promotions, product information and service offers. Please be aware that this information may be stored on a server located in the U.S. If you do not consent to this use of your personal information, please do not use this system.

  • Submit

Thank You

Thank you for requesting a product evaluation. Someone from our team will contact you soon!

Our Apologies...

An error has occurred while submitting. Please try again later.

How PREVENA™ Therapy works
How PREVENA™ Therapy works

Knee with PREVENA™ Therapy
Now more than ever.

PREVENA™ Therapy is uniquely engineered to empower incision management that works to protect patients, surgeons, staff, practices, and hospitals during the SARS-CoV-2 pandemic.

LEARN MORE ABOUT PREVENA™ Incision Management System

Subscribe to receive the latest 3M Medical news, events and information.

Call us on 1-800-228-3957

Call us on 1-800-228-3957

Close  
  • *PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, PREVENA™ 125 and PREVENA PLUS™ 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and II wounds.

    The effectiveness of PREVENA™ Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at myKCI.com.